share_log

Maxim Group Initiates Coverage On NeuroBo Pharmaceuticals With Buy Rating, Announces Price Target of $10

Maxim Group Initiates Coverage On NeuroBo Pharmaceuticals With Buy Rating, Announces Price Target of $10

Maxim集團以買入評級啓動對NeuroBO製藥的報道,宣佈目標股價爲10美元
Benzinga ·  05/08 22:08

Maxim Group analyst Jason McCarthy initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announces Price Target of $10.

Maxim Group分析師Jason McCarthy開始對神經保健製藥(納斯達克:NRBO)進行覆蓋,給予買入評級,並公佈目標價爲10美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論